All In Biotech

Drug Trial Radar · NCT03020602

BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab

A Phase I Study of BPM31510 Plus Vitamin K in Subjects With High-Grade Glioma That Has Recurred on a Bevacizumab Containing Regimen

Last checked: Nov 19, 2026Latest source record: Aug 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Jan 4, 2017

Primary completion

Apr 4, 2019

Study completion Jun 26, 2021

Sponsor

Lead sponsor
Seema NagpalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial studies the side effects and best dose of ubidecarenone injectable nanosuspension (BPM31510) in treating patients with high-grade glioma (anaplastic astrocytoma or glioblastoma) that has come back and have been previously treated with bevacizumab. BPM31510 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Gliosarcoma
  • Recurrent Glioblastoma
  • Astrocytoma of Brain
  • Glioblastoma

Interventions

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • Pharmacological StudyOther

    Correlative studies

  • Ubidecarenone Injectable NanosuspensionDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients with dose-limiting toxicities defined as thrombocytopenia >= grade 3, hemorrhage >= grade 3, and INR elevation >= grade 2 assessed by CTCAE v4.03Time frame: Up to 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stanford University, School of Medicine

    Palo Alto, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.